Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 11;2:48. doi: 10.1038/s43856-022-00114-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Heatmap showing the antibody response to melanoma-antigens in patients with cancer and in the controls. Log₁₀-transformation of the average abundance of the IgG-bound peptides containing epitopes with 100% identity to the indicated proteins are depicted. Value range ≤ 2.4 and ≥ 3.3 is provided for better visual representation. Group names of samples are depicted on the y-axis, individuals shown in numbers. x-axis indicates different melanoma-associated antigens (a total of 35 proteins) shown in Supplementary Table 3 and Supplementary Data 3. b, c Violin plots showing the average abundance of IgG-bound peptides containing epitopes with 100% identity to the specific proteins (shown above each graph, Supplementary Data 4) from panel a across study sub-cohorts. Two-sided Wilcoxon Rank Sum test, ns p > 0.5, *p < 0.05, **p < 0.01, *** p < 0.001, **** p < 0.0001, p-values not adjusted for multiple comparisons. CTRL-Mel – healthy controls for melanoma group (n = 21, all individuals older than 45 years); PEM-Mel – melanoma patients receiving pembrolizumab treatment (n = 5); MelVac-CTRL – paired samples of MelVac group taken before vaccination (n = 6); MelVac – NSCLC patients who received MelCancerVac^® vaccine (n = 6); NSCLC – non-small cell lung cancer patients (n = 18).